AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15119922
Drug: Olanzapine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (up to 20 mg/day)
Trial: 11231440
Drug: ANP (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANP (30 ng/kg/min) infusion before and after ACEi treatment (n = 9)
Trial: 11231440
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of ANP with acute saline solution load (n = 8)
Trial: 11231440
Drug: Acute saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute saline solution loading (n = 8)
Trial: 9566811
Drug: Physostigmine (maximal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (maximal tolerated dose)
Trial: 4400530
Drug: M &
RxNorm normalized name: Publix Calcium & D Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M & B 17803A (300 mg)
Trial: 4400530
Drug: Propranolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (10 and 40 mg)
Trial: 4400530
Drug: M &
RxNorm normalized name: Publix Calcium & D Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M & B 17803A (small oral doses)
Trial: 31371154
Drug: Topical haemostatic
RxNorm normalized name: collagen hemostat Topical Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical haemostatic agents (oxidized cellulose or collagen) + fibrin glue (experimental group with VADs)
Trial: 31371154
Drug: Topical haemostatic
RxNorm normalized name: collagen hemostat Topical Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical haemostatic agents (oxidized cellulose or collagen) (control group)
Trial: 26043724
Drug: AZD9668 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9668 60 mg twice daily (BID)
Trial: 26043724
Drug: AZD9668 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9668 60 mg BID
Trial: 23704939
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg apomorphine
Trial: 18953498
Drug: Antihypertensive agent
RxNorm normalized name: Antihypertensive agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive agent (parenteral or oral)
Trial: 18953498
Drug: Both IV
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both IV MgSO(4) and antihypertensive agent
Trial: 3132034
Drug: Zinc supplement
RxNorm normalized name: Zinc supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplement of 50 mg daily for 2 weeks
Trial: 3132034
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no zinc supplement)
Trial: 18269927
Drug: Omalizumab 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab 0.015 mg/kg/IU/mL every 2 weeks for 28 weeks
Trial: 18269927
Drug: Omalizumab 0.030
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab 0.030 mg/kg/IU/mL every 2 weeks for 28 weeks
Trial: 18269927
Drug: Reduced doses
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced doses of omalizumab (0.0015 or 0.0050 mg/kg/IU/mL every 2 weeks for 18 weeks)
Trial: 18269927
Drug: Complete discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete discontinuation of omalizumab therapy
Trial: 12850599
Drug: Advance provision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advance provision of emergency contraception (8 oral contraceptive pills containing 0.15 mg of levonorgestrel and 30 microg of ethinyl estradiol) and a 5-minute educational session
Trial: 7484285
Drug: Alendronate 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 2.5 mg
Trial: 2271372
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (8 g)
Trial: 14585761
Drug: LIPC‐480 CC/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIPC‐480 CC/CT genotype with normal physical activity (reference group)
Trial: 11056771
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (nodraparin calcium, Fraxiparine) administered according to body weight
Trial: 1457788
Drug: Manganese DPDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manganese DPDP (5 mumol/kg, 10 mumol/ml concentration)
Trial: 31282364
Drug: Subcutaneous liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous liraglutide
Trial: 23002259
Drug: 10 mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg, 0.5% hyperbaric bupivacaine with the Whitacre needle oriented laterally
Trial: 23002259
Drug: 10 mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg, 0.5% hyperbaric bupivacaine with the Whitacre needle oriented cephalad
Trial: 15676041
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral artemisinin daily for 5 days
Trial: 15676041
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of 100/100/250/250/500 mg on each of the first 5 days
Trial: 10359405
Drug: Budesonide 800
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 800 microg plus 400 microg daily for 6 months followed by 400 microg twice daily for 30 months
Trial: 2127335
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg vancomycin administered into the ventricular system during surgery
Trial: 31006038
Drug: Sunitinib 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 15 mg/m2 per day, 4-weeks-on/2-weeks-off (schedule 4/2), with intra-patient dose escalation to 22.5 and subsequently 30 mg/m2 based on tolerability.
Trial: 30061768
Drug: Nanosil mouthwash
RxNorm normalized name: Nanosilver
DrugBank: Silver (DB12965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanosil mouthwash (oral decontamination program performed three times a day for five days)
Trial: 30061768
Drug: Chlorhexidine 0.12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine 0.12% (oral decontamination program performed three times a day for five days)
Trial: 19884037
Drug: Cervical spine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical spine manual therapy (lateral glide)
Trial: 17335465
Drug: Lamotrigine 25
RxNorm normalized name: lamotrigine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 25 mg twice daily
Trial: 17335465
Drug: Amitriptyline 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 10, 25, and 50 mg at night-time
Trial: 17335465
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Lamotrigine and Amitriptyline)
Trial: 10344555
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy (Mitoxantrone: 45 mg/m2, Cyclophosphamide: 120 mg/kg, Melphalan: 140 mg/m2)
Trial: 10344555
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (conventional chemotherapy)
Trial: 1758944
Drug: Support therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Support therapy
Trial: 26577683
Drug: Twice-daily budesonide
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily budesonide 2mg foam
Trial: 24480430
Drug: PBSC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBSC group received subcutaneous G-CSF injections (15 µg/kg/day) for 5 consecutive days, followed by stereotaxic implantation of 3-8 × 10(6) CD34(+) immunosorted PBSCs.
Trial: 17598500
Drug: Comprehensive, population-based,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive, population-based, organised cervical cancer prevention programmes integrating cervical screening with new technologies and vaccines
Trial: 15768872
Drug: Qingxin capsule
RxNorm normalized name: SILICON DIOXIDE 14 g in 100 g / .ALPHA.-TOCOPHEROL ACETATE 0.1 g in 100 g / SODIUM PYROPHOSPHATE 0.5 g in 100 g DENTAL PASTE, DENTIFRICE [Mastikis Qingxin Care Mastic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingxin capsule (QXC)
Trial: 9505778
Drug: Pirenzepine 25
RxNorm normalized name: pirenzepine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 25 mg + Ranitidine 75 mg
Trial: 343743
Drug: Naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 250 mg twice a day
Trial: 343743
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg taken at bedtime
Trial: 11755835
Drug: Indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 25 mg four times a day
Trial: 343743
Drug: Naproxen (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (single daily dose)
Trial: 17356963
Drug: Medication databases
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication databases
Trial: 15687448
Drug: PI-containing combination
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI-containing combination therapy
Trial: 12351435
Drug: Troglitazone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (600 mg/day) for 3 months
Trial: 10072479
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg thioctic acid (TA)
Trial: 10072479
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg thioctic acid (TA)
Trial: 7552589
Drug: Carbohydrate intake
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate intake of 8 g/kg/day (5.5 mg/kg/minute)
Trial: 7552589
Drug: Carbohydrate intake
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate intake of 12 g/kg/day (8.3 mg/kg/minute)
Trial: 31464626
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) integrated treatment program including tripterygium glycosides (TGs), tanshinone IIa sodium sulfonate injection, and Chinese herbs based on syndrome differentiation
Trial: 31464626
Drug: Benazepril hydrochloride
RxNorm normalized name: Benazepril Hydrochloride
DrugBank: Benazepril (DB00542)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benazepril hydrochloride tablets, low molecular weight heparin calcium injection, dipyridamole tablets, and a Chinese medicine placebo
Trial: 31464626
Drug: Benazepril hydrochloride
RxNorm normalized name: Benazepril Hydrochloride
DrugBank: Benazepril (DB00542)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benazepril hydrochloride tablets, low molecular weight heparin calcium injection, dipyridamole tablets, a Chinese medicine placebo, and prednisone
Trial: 25244414
Drug: Probiotic therapy
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic therapy (Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus rhamnosus, and Streptococcus thermophilus) for 4 weeks
Trial: 12040670
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy plus surgical salvage treatment
Trial: 22392456
Drug: Citalopram (first-step
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (first-step treatment)
Trial: 22392456
Drug: Sustained-release bupropion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release bupropion, sertraline, or extended-release venlafaxine (second-step treatment)
Trial: 93297
Drug: gamma-globulin 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gamma-globulin 16 Merieux (1 ml/kg)
Trial: 31118057
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) at 4 J/cm2
Trial: 19934423
Drug: ACLS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACLS with intravenous drug administration
Trial: 19934423
Drug: ACLS without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACLS without intravenous drug administration
Trial: 16476841
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (EPO), 10,000 U three times weekly s.c.
Trial: 10677157
Drug: Heparin group
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin group (maintaining a whole blood heparin concentration of 3 mg/kg)
Trial: 24521107
Drug: Oxantel pamoate
RxNorm normalized name: OXANTEL PAMOATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxantel pamoate (20 mg/kg) plus albendazole (400 mg)
Trial: 20715734
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (target glycaemic control: 4.4 to 6.1 mmol/l)
Trial: 20715734
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin therapy (target control: 10.0 to 11.1 mmol/l)
Trial: 20715734
Drug: Glycaemic fluctuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycaemic fluctuation (mean difference between highest and lowest daily blood glucose)
Trial: 18023151
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of parenteral veterinary preparation of ivermectin
Trial: 18023151
Drug: 7-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day course of oral albendazole 800 mg daily
Trial: 10619727
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg) daily for 14 days
Trial: 8949765
Drug: Fast neutron
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast neutron therapy alone or in combination with photons
Trial: 7282596
Drug: Warfarin (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (0.01 mg/100 g, IP) with vitamin E (1000 units/kg IM for 7 days) in rats
Trial: 26025128
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (OCS) - short-term oral prednisone bursts during acute asthma exacerbations
Trial: 14747807
Drug: Delayed-release acetaminophen
RxNorm normalized name: acetaminophen Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release acetaminophen preparation (75 mg/kg) with whole bowel irrigation
Trial: 11878526
Drug: 2.5 ml
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 ml of 7.5 mg ml(-1) ropivacaine (18.75 mg)
Trial: 11878526
Drug: 2.5 ml
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 ml of 10 mg ml(-1) ropivacaine (25 mg)
Trial: 9492256
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of itraconazole 40‐mg/mL oral suspension
Trial: 9492256
Drug: Four 100‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four 100‐mg itraconazole capsules
Trial: 9492256
Drug: Hydroxyitraconazole from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyitraconazole from the suspension
Trial: 9492256
Drug: Hydroxyitraconazole from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyitraconazole from the capsules
Trial: 2839280
Drug: Adriamycin 60
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin 60 to 75 mg/m2 at 3-week intervals
Trial: 24814388
Drug: Mericitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mericitabine (1000 mg) and ritonavir-boosted danoprevir (100 mg/100 mg) plus ribavirin (1000/1200 mg/day) for 24 weeks
Trial: 24814388
Drug: Mericitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mericitabine (1000 mg) and ritonavir-boosted danoprevir (100 mg/100 mg) without ribavirin (Arm B) for 24 weeks
Trial: 23911183
Drug: Sensor-augmented pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-augmented pump therapy with threshold suspend
Trial: 21744200
Drug: Handpiece removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Handpiece removal of mini-implants
Trial: 21744200
Drug: Manual removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual removal of mini-implants
Trial: 21744200
Drug: No local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No local anesthetic injection
Trial: 16484892
Drug: Glibenclamide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (20 mg)
Trial: 14574783
Drug: High-dose paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose paracetamol (6 g daily)
Trial: 9411418
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy (mean daily dose 18 +/- 8 U)
Trial: 1551536
Drug: Clonidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (150 micrograms single dose)
Trial: 1551536
Drug: Clonidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (150 micrograms single dose and 150 micrograms/day for 1 week)
Trial: 25046070
Drug: Desloratadine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine (5 mg/d)
Trial: 17393438
Drug: Gabapentin (1,200-2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1,200-2,400 mg/day)
Trial: 12049678
Drug: Esmolol (24-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (24-hour infusion starting 6-18 hours after CABG at an average dose of 67 +/- 7 microg/kg/min)
Trial: 12049678
Drug: Oral beta-blockers
RxNorm normalized name: beta carotene Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beta-blockers only (starting on postoperative day 1)
Trial: 4561679
Drug: Bromhexine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine (24 mg or 48 mg daily)
Trial: 22092124
Drug: Triple prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple prophylaxis (dexamethasone 8 mg IV, ondansetron 4 mg IV, droperidol 0.625 mg IV)
Trial: 16340950
Drug: Iron plus
RxNorm normalized name: Nu-Iron Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron plus iodine (190 mg iodine + 300 mg ferrous sulphate 5 times/week, n=24)
Trial: 16340950
Drug: Iron (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (300 mg ferrous sulphate 5 times/week, n=23)
Trial: 16340950
Drug: Iodine (190
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine (190 mg iodine, n=25)
Trial: 9121326
Drug: Rifampicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin plus ofloxacin administered daily for 4 weeks
Trial: 3721646
Drug: Salmon calcitonin
RxNorm normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon calcitonin 100 IU i.m. daily for 30 days
Trial: 30138966
Drug: Adiponectin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adiponectin (20 μg/ml for 30 minutes)
Trial: 30427152
Drug: Decrease of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease of ionized calcium content (till 0.32 mmole/l) in venous blood
Trial: 30427152
Drug: Increase of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase of lactate content (up to 4.1 mmole/l) in venous blood
Trial: 24415567
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control (pseudo‐placebo monotherapy)
Trial: 7853417
Drug: Etoposide and
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide and cisplatin plus twice-daily chest radiotherapy (n = 54)
Trial: 7853417
Drug: Standard-dose etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose etoposide plus cisplatin (n = 46)
Trial: 7853417
Drug: High-dose etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose etoposide plus cisplatin (n = 44)
Trial: 7853417
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose etoposide plus cisplatin for poor-risk patients (n = 25)
Trial: 31162017
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (6 months deferred)
Trial: 21574777
Drug: Creatine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (20 g·day(‐1) for 1 week and 5 g·day(‐1) thereafter)
Trial: 11378339
Drug: Chemotherapy (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (doxorubicin 50 mg/m² i.v. bolus and ifosfamide 5 g/m² 24 h infusion)
Trial: 11378339
Drug: Chemotherapy (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (doxorubicin and ifosfamide)
Trial: 8357473
Drug: Sublingual specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual specific immunotherapy with purified and standardised allergen (Stallergenes '5-grass pollen')
Trial: 3511392
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg 5 X in 30 h)